Isis Pharmaceuticals to Present at the Stifel Nicolaus Healthcare Conference 2011

CARLSBAD, Calif., Sept. 1, 2011 /PRNewswire/ — Isis
Pharmaceuticals, Inc. (Nasdaq:
ISIS), the leader in antisense therapeutics, today announced
that management will present a company overview at Stifel Nicolaus’
Healthcare Conference 2011 on Thursday, September 08, 2011 at 2:05
p.m. ET at the Four Seasons Hotel in Boston.

A live audio webcast of the presentation will be available on
the “Investors & Media” section of the Company’s Web site, www.isispharm.com.  A
replay of the presentation will be available on the Isis Web site
within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense
technology to discover and develop novel drugs for its product
pipeline and for its partners.  Isis’ broad pipeline consists
of 24 drugs to treat a wide variety of diseases with an emphasis on
cardiovascular, metabolic and severe and rare/neurodegenerative
diseases, and cancer.  Isis’ partner, Genzyme, plans to
commercialize Isis’ lead product, mipomersen following regulatory
approval, which is expected in 2012.  Isis’ patents provide
strong and extensive protection for its drugs and technology.
 Additional information about Isis is available at www.isispharm.com.

‘/>”/>

SOURCE